Phase II Single Arm Study of Everolimus and Pasireotide (SOM230) in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC).
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2016
At a glance
- Drugs Everolimus (Primary) ; Pasireotide (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 23 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Mar 2014 Planned End Date changed from 1 Jun 2013 to 1 Jun 2015 as reported by ClinicalTrials.gov.
- 28 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.